Related Experiment Video

Updated: Aug 20, 2026

Full-Circle Cauterization of Limbal Vascular Plexus for Surgically Induced Glaucoma in Rodents
10:10

Full-Circle Cauterization of Limbal Vascular Plexus for Surgically Induced Glaucoma in Rodents

Published on: February 15, 2022

p21WAF-1/Cip-1 gene therapy as an adjunct to glaucoma filtration surgery

Isabella A Atencio1, Zoe Chen, Quang H Nguyen

  • 1Canji Inc, 3525 John Hopkins Court, San Diego, CA 92121, USA.

Current Opinion in Molecular Therapeutics
|January 25, 2005
PubMed

Insights

Ocular gene therapy using rAd-p21 shows promise in controlling wound healing after glaucoma filtration surgery (GFS). This approach may offer a safer alternative to anti-metabolites for preventing surgical failure and preserving vision.

Area of Science:

  • Ophthalmology
  • Molecular Biology
  • Regenerative Medicine

Background:

  • Glaucoma is a leading cause of blindness, often managed with glaucoma filtration surgery (GFS).
  • Post-surgical wound healing can lead to GFS failure, necessitating further interventions.
  • Current anti-metabolite treatments for wound modulation have significant side effects.

Purpose of the Study:

  • To review the therapeutic potential of ocular gene therapy for modulating wound healing post-GFS.
  • To evaluate the use of an adenovirus vector carrying the human p21WAF-1/Cip-1 gene (rAd-p21) as a novel treatment strategy.

Main Methods:

  • Review of preclinical data from relevant animal models.
  • Analysis of gene therapy mechanisms targeting cellular proliferation and wound response.

Main Results:

  • Preclinical data suggest rAd-p21 effectively controls wound healing responses.
  • The gene therapy approach demonstrates potential for IOP reduction and sustained surgical success.

Conclusions:

  • Ocular gene therapy with rAd-p21 presents a promising alternative to current anti-metabolite treatments.
  • rAd-p21 gene therapy offers a potentially safer and more effective method for modulating wound healing after GFS.

Related Concept Videos

Angle Closure Glaucoma: Treatment01:28

Angle Closure Glaucoma: Treatment

Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
Open Angle Glaucoma: Treatment01:27

Open Angle Glaucoma: Treatment

In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Glaucoma: Overview01:25

Glaucoma: Overview

Glaucoma is an eye condition characterized by increased intraocular pressure that damages the retina and optic nerve, leading to irreversible blindness if left untreated. The human eye has various components, including the cornea, iris, pupil, lens, and optic nerve. Aqueous humor is secreted by the epithelium of the ciliary body in the posterior chamber and flows through the trabecular meshwork and canal of Schlemm, maintaining normal intraocular pressure. The trabecular meshwork and the canal...